Visualization of Proteins and Cells Using Dithiol‐reactive Metal Complexes

Park, Danielle; Shon, Ivan Ho; Hua, Minh; Chen, Vivien; Hogg, Philip J.

doi:10.1002/9781118682975.ch7

Cited by 4 publications

(6 citation statements)

References 78 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…282 Moreover, the high abundance of Hsp90 within the cytoplasm allows high accumulation of GSAO-based probes in dying and dead cells with loss of plasma membrane integrity. 281,282 All the evidence makes Hsp90 an attractive target for noninvasive visualization of cell death.…”

Section: ■ Necrosis Imagingmentioning

confidence: 99%

“…281 However, no absolute uptake difference of 67 Ga-GSAO between treated and untreated tumors was observed. 281 This led to the attempt to develop a 68 Ga-labeled GSAO ( 68 Ga-GSAO) for PET imaging, which allows for frequent sequential imaging before and after therapy, as it is thought that the incremental change following therapy may be more useful than the absolute uptake. Recently, the same research group reported the preparation of 68 Ga-GSAO, which showed good biodistribution and imaging characteristics.…”

Section: ■ Necrosis Imagingmentioning

confidence: 99%

“…It plays an important role in cellular homeostasis and tumorigenesis, for example, assisting in folding and stabilization of numerous mutated and overexpressed oncoproteins. , When the integrity of cell plasma membrane is compromised, Hsp90 becomes accessible to bind by molecular imaging probes. Hsp90 has been targeted by the conjugates of 4-( N -(S-glutathionylacetyl)amino)phenylarsonous acid (GSAO) with different reporter groups for noninvasive imaging of cell death in different animal models. − Hsp90 contains two closely spaced Cys597, Cys598 thiols, which can be selectively cross-linked by tripeptide trivalent arsenical GSAO to form a stable and irreversible cyclic dithioarsinite in intracellular milieu . Moreover, the high abundance of Hsp90 within the cytoplasm allows high accumulation of GSAO-based probes in dying and dead cells with loss of plasma membrane integrity. , All the evidence makes Hsp90 an attractive target for noninvasive visualization of cell death.…”

Section: Necrosis Imagingmentioning

confidence: 99%

“…Moreover, it was demonstrated that noninvasive visualization of tumor cell death could also be achieved using 111 In-labeled GSAO ( 111 In-GSAO) by SPECT/CT imaging . Subsequently, a 67 Ga-labeled GSAO ( 67 Ga-GSAO) was prepared and found to have slightly higher tumor uptake and significantly lower uptake in normal organs than that of 111 In-GSAO . However, no absolute uptake difference of 67 Ga-GSAO between treated and untreated tumors was observed .…”

Section: Necrosis Imagingmentioning

confidence: 99%

“…Subsequently, a 67 Ga-labeled GSAO ( 67 Ga-GSAO) was prepared and found to have slightly higher tumor uptake and significantly lower uptake in normal organs than that of 111 In-GSAO . However, no absolute uptake difference of 67 Ga-GSAO between treated and untreated tumors was observed . This led to the attempt to develop a 68 Ga-labeled GSAO ( 68 Ga-GSAO) for PET imaging, which allows for frequent sequential imaging before and after therapy, as it is thought that the incremental change following therapy may be more useful than the absolute uptake.…”

Section: Necrosis Imagingmentioning

confidence: 99%

See 4 more Smart Citations

Imaging Cell Death: Focus on Early Evaluation of Tumor Response to Therapy

et al. 2020

View full text Add to dashboard Cite

Cell death plays a prominent role in the treatment of cancer, because most anticancer therapies act by the induction of cell death including apoptosis, necrosis, and other pathways of cell death. Imaging cell death helps to identify treatment responders from nonresponders and thus enables patient-tailored therapy, which will increase the likelihood of treatment response and ultimately lead to improved patient survival. By taking advantage of molecular probes that specifically target the biomarkers/biochemical processes of cell death, cell death imaging can be successfully achieved. In recent years, with the increased understanding of the molecular mechanism of cell death, a variety of well-defined biomarkers/biochemical processes of cell death have been identified. By targeting these established cell death biomarkers/biochemical processes, a set of molecular imaging probes have been developed and evaluated for early monitoring treatment response in tumors. In this review, we mainly present the recent advances in identifying useful biomarkers/biochemical processes for both apoptosis and necrosis imaging and in developing molecular imaging probes targeting these biomarkers/biochemical processes, with a focus on their application in early evaluation of tumor response to therapy.

show abstract

Section: ■ Necrosis Imagingmentioning

confidence: 99%